HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025MIRAMAR, Fla., June 04, 2025 (GLOBE ...

Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) ...

Ocugen signs binding term sheet for license of OCU400 modifier gene therapy for retinitis pigmentosa in Korea: Malvern, Pennsylvania Saturday, June 7, 2025, 16:00 Hrs [IST] Ocugen ...

Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Vera Therapeutics (VERA) stock faces a 32% drop as its IgAN drug trails Otsuka's (ORSKY) rival in late-stage trials. Read ...

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...

Analysts reacted positively to the news that uniQure is in alignment with the FDA on an accelerated approval pathway and on ...

Regenxbio (RGNX) stock in focus as the company shares promising trial data for its RGX-202 gene therapy for Duchenne muscular ...

ADMA Biologics ADMA has been a consistent market outperformer in recent times. Shares have gained 17.2% in the past three ...

Investing.com -- Shares of Ocugen, Inc. (NASDAQ: OCGN) climbed 11.6% following the announcement of a licensing agreement with a leading Korean pharmaceutical company for the rights to OCU400, its gene ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...